Updates in CLL

CE / CME

Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Registered Nurses: 1.00 Nursing contact hour

Physician Assistants: maximum of 1.00 hour of AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: April 22, 2025

Expiration: October 21, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following was demonstrated in the interim analysis of results from the phase III AMPLIFY trial of fixed duration Acalabrutinib (A) + Venetoclax (V) ± Obinutuzumab (O) vs FCR/BR for untreated CLL without del(17p) or TP53 mutations?

2.

Patient Case: A 76-Yr-Old Woman With Previously Untreated CLL



  • 76-yr-old woman was diagnosed with CLL in 2023

    • Rai stage 1, IGHV unmutated, FISH reveals del(17p)



  • Patient has a long-standing history of hypertension controlled with 3 medicines, coronary artery disease controlled medically, atrial fibrillation which was controlled, and baseline creatinine of 1.8

  • Initially, patient was followed with watchful waiting but developed PD in 2024

  • Workup revealed Hb of 9.9, white count of 77, and platelet of 90K

  • CT scan revealed bulky axillary nodes of 7 cm bilateral and retroperitoneal nodes of 9 cm

  • Patient has difficulty with mobility due to arthritis and lives 3 hr from the treatment center

  • She is worried about travel requirements and wants to start treatment that gives her the best outcome 

Which of the following would you recommend as the best first-line therapy for this patient?

3.

Patient Case: An 86-Yr-Old Man With Relapsed CLL



  • An 86-yr-old man was diagnosed with CLL in 2013

    • Rai stage 1, IGHV unmutated, FISH reveals trisomy 12



  • S/p prior treatment with bendamustine + rituximab in 2014, followed by venetoclax + rituximab from 2016 to 2018

  • In 2019 he was started on acalabrutinib and achieved good disease control

  • He remained on acalabrutinib but recently developed worsening lymphocytosis and lymphadenopathy concerning for progressive disease

  • NGS revealed acquired BTK C481S mutation

  • He states that he would prefer another oral therapy in his next line of treatment 

Which of the following would you recommend as the best next-line therapy for this patient?